Catalent Expands Biologics Packaging Capacity

Article

Catalent Biologics increased capacity at its Bloomington, IN Facility.

Catalent announced in an April 23, 2020 press release that it completed its $14 million expansion to increase the biologics packaging capabilities and capacity at its Bloomington, IN facility. The company added 15,000-ftof packaging infrastructure to the existing biologics and sterile manufacturing site, including five new packaging suites and a new quality control laboratory.

Three new packaging lines include an Optima combination syringe assembly machine, an automated Mikron auto-injector assembly machine, and a Dividella NeoTOP x (NTX) top-load cartoner with both semi-automated and fully-automated configurations. All three high-speed lines are fully qualified and ready to provide customers faster and more flexible packaging solutions for vials, syringes, and devices with no glass-to-glass contact.

“The completion of this expansion marks a major milestone for our late-stage and commercial customers, allowing Catalent to focus on more complex device assembly and packaging needs for biologic products at higher volumes,” commented Mike Riley, region president, Biologics North America, in the press release. “This state-of-the-art equipment adds to our growing network of global packaging capabilities alongside our Brussels, Belgium, and Anagni, Italy drug product manufacturing sites.”

Source: Catalent

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content